Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 28Leukemia 8Recurrence 6Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 2Solid Tumors 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies 1Aortic aneurysm, familial thoracic 4 1

Interventions

Cyclophosphamide 56Cytarabine 43fludarabine phosphate 37Methotrexate 35Whole-Body Irradiation 32Mycophenolic Acid 29Filgrastim 27fludarabine 25Peripheral Blood Stem Cell Transplantation 22Vincristine 21Cyclosporine 20Busulfan 19Dexamethasone 18Specimen Handling 17Methylprednisolone 17venetoclax 16Granulocyte Colony-Stimulating Factor 16Tacrolimus 15Hydrocortisone 15Melphalan 14Daunorubicin 14Asparaginase 14merphos 13Thiotepa 13Mercaptopurine 13Leucovorin 13Cord Blood Stem Cell Transplantation 13Antilymphocyte Serum 13Calcium Dobesilate 11Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × quizartinib × Clear all
NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡